The international normalized ratio to prioritize patients for liver transplantation: Problems and possible solutions

Journal of Thrombosis and Haemostasis

Volumn 6, Issue 2, 2008, Pages 243-248

  Tripodi, Armando ^a,b   Chantarangkul, V ^a   Mannucci, P M ^a  

^a FONDAZIONE IRCCS CA GRANDA OSPEDALE MAGGIORE POLICLINICO   (Italy)

^b NONE   (Italy)

Author keywords

Chronic liver disease; International normalized ratio; Model of end stage liver disease; Standardization

Indexed keywords

ANTICOAGULANT AGENT; ANTIVITAMIN K; BLOOD CLOTTING FACTOR 5; CARBOXYLASE; FIBRINOGEN; PROTHROMBIN; THROMBOPLASTIN;

ANTICOAGULATION; CALIBRATION; CHRONIC LIVER DISEASE; DRUG PROTEIN BINDING; GRAFT SURVIVAL; HUMAN; INTERNATIONAL NORMALIZED RATIO; LIVER TRANSPLANTATION; MATHEMATICAL MODEL; OBSTRUCTIVE JAUNDICE; PATIENT MONITORING; PRIORITY JOURNAL; PROTEIN SYNTHESIS INHIBITION; PROTHROMBIN TIME; REVIEW; VALIDATION STUDY; WORLD HEALTH ORGANIZATION;

EID: 38349193435     PISSN: 15387933     EISSN: 15387836     Source Type: Journal    
DOI: 10.1111/j.1538-7933.2008.02827.x     Document Type: Review

References (31)

1. Hedner U, Erhardtsen E. Hemostatic disorders in liver disease. In: Schiff ER, Sorrell MF, Maddrey WC, eds. Diseases of the Liver. Philadelphia: Lippincott Williams and Wilkins, 2003: 625-35.
2. Hollestelle MJ, Geertzen HG, Straatsburg IH, van Gulik TM, van Mourik JA. Factor VIII expression in liver disease. Thromb Haemost 2004; 91: 267-75.
3. Lisman T, Bongers TN, Adelmeijer J, Janssen HL, de Maat MP, de Groot PG, Leebeek FW. Elevated levels of von Willebrand factor in cirrhosis support platelet adhesion despite reduced functional capacity. Hepatology 2006; 44: 53-61.
4. Caldwell SH, Hoffman M, Lisman T, Macik BG, Northup PG, Reddy KR, Tripodi A, Sanyal AJ; Coagulation in Liver Disease Group. Coagulation disorders and hemostasis in liver disease: Pathophysiology and critical assessment of current management. Hepatology 2006; 44: 1039-46.
5. Tripodi A, Salerno F, Chantarangkul V, Clerici M, Cazzaniga M, Primignani M, Mannuccio Mannucci P. Evidence of normal thrombin generation in cirrhosis despite abnormal conventional coagulation tests. Hepatology 2005; 41: 553-8.
6. Tripodi A, Primignani M, Chantarangkul V, Clerici M, Dell'Era A, Fabris F, Salerno F, Mannucci PM. Thrombin generation in patients with cirrhosis: The role of platelets. Hepatology 2006; 44: 440-5.
7. Dahlback B. Progress in the understanding of the protein C anticoagulant pathway. Int J Hematol 2004; 79: 109-16.
8. Huntington JA. Mechanisms of glycosaminoglycan activation of the serpins in hemostasis. J Thromb Haemost 2003; 1: 1535-49.
9. van Wijngaarden A, van den Besselaar AM, Bertina RM. Thrombomodulin activity in commercial thromboplastin preparations. Thromb Res 1986; 43: 265-74.
10. Ewe K. Bleeding after liver biopsy does not correlate with indices of peripheral coagulation. Dig Dis Sci 1981; 26: 388-93.
11. Segal JB, Dzik WH. Paucity of studies to support that abnormal coagulation test results predict bleeding in the setting of invasive procedures: An evidence-based review. Transfusion 2005; 45: 1413-25.
12. Pugh RN, Murray-Lyon IM, Dawson JL, Pietroni MC, Williams R. Transaction of the oesophagus for bleeding oesophageal varices. Br J Surg 1973; 60: 646-9.
13. Malinchoc M, Kamath PS, Gordon FD, Peine CJ, Rank J, ter Borg PC. A model to predict poor survival in patients undergoing transjugular intrahepatic portosystemic shunts. Hepatology 2000; 31: 864-71.
14. Wiesner R, Edwards E, Freeman R, Harper A, Kim R, Kamath P, Kremers W, Lake J, Howard T, Merion RM, Wolfe RA, Krom R. United Network for Organ Sharing Liver Disease Severity Score Committee. Model for end-stage liver disease (MELD) and allocation of donor liver. Gastroenterology 2003; 124: 91-6.
15. Trotter JF, Brimhall B, Arjal R. Specific laboratory methodologies achieve higher model for endstage liver disease (MELD) scores for patients listed for liver transplantation. Liver Transpl 2004; 10: 995-1000.
16. United Network for Organ Sharing 2007. http://www.unos.org/ SharedContentDocuments/Revised_MELDPELD_2003(2).pdf; accessed 24 August 2007.
17. Kenison J, Arjal R, Smith A, Brimball B, Phillips C, Olson J, Lefkowitz J, Trotter J. Interlaboratory variation in INR leads to clinically relevant changes in the MELD score. Surveys of clinical laboratories. Am J Transpl 2006; 6 (Suppl. 2): 333.
18. Robert A, Chazouilleres O. Prothrombin time in liver failure: Time, ratio, activity percentage, or international normalized ratio. Hepatology 1996; 24: 1392-4.
19. Kovacs MJ, Wong A, MacKinnon K, Weir K, Keeney M, Boyle E, Cruickshank M. Assessment of the validity of the INR system for patients with liver impairment. Thromb Haemostas 1994; 71: 727-30.
20. Denson KW, Reed SV, Haddon ME, Woodhams B, Brucato C, Ruiz J. Comparative studies of rabbit and human recombinant tissue factor reagents. Thromb Res 1999; 94: 255-61.
21. van den Besselaar AMHP, Poller L, Tripodi A. Guidelines for thromboplastins and plasmas used to control oral anticoagulant therapy (1999). WHO Tech Rep Ser 1999; 889: 64-93.
22. Furie B, Furie BC. Molecular basis of vitamin K-dependent gamma-carboxylation. Blood 1990; 75: 1753-62.
23. Deitcher SR. Interpretation of the international normalised ratio in patients with liver disease. Lancet 2002; 359: 47-8.
24. Tripodi A, Chantarangkul V, Primignani M, Fabris F, Dell'Era A, Sei C, Mannucci PM. The international normalized ratio calibrated for cirrhosis (INR liver) normalizes prothrombin time results for model for end-stage liver disease calculation. Heaptology 2007; 46: 520-7.
25. Bellest L, Eschwege V, Poupon R, Chazoullieres O, Robert A. A modified international normalized ratio as an effective way of prothrombin time standardization in hepatology. Hepatology 2007; 46: 528-34.
26. Tomenson JA. A statistician's independent evaluation. In: Van den Besselaar AMHP, Lewis SM, Gralnick HR, eds. Thromboplastin Calibration and Oral Anticoagulant Control. Boston: Martinus Nijhoff, 1984: 87-108.
27. Chantarangkul V, van den Besselaar AM, Witteveen E, Tripodi A. International collaborative study for the calibration of a proposed international standard for thromboplastin, rabbit, plain. J Thromb Haemost 2006; 4: 1339-45.
28. van den Besselaar AMHP, Houbouyan LL, Aillaud MF, Denson KW, Johnston M, Kitchen S, Lindahl TL, Marren M, Martinuzzo ME, Droulle C, Tripodi A, Vergnes C. Influence of three types of automated coagulometers on the international sensitivity index (ISI) of rabbit, human, and recombinant human tissue factor preparations - a multicenter study. Thromb Haemost 1999; 81: 66-70.
29. van den Besseaar AMHP, Barrowcliffe TW, Houbouyan-Reveillard LL, Jespersen J, Johnston M, Poller L, Jespersen J, Johnston M, Poller L, Tripodi A, on behalf of the Subcommittee on Control of Anticoagulation of the Scientific and Standardization Committee of the ISTH. Guidelines on preparation, certification and use of certified plasmas for ISI calibration and INR determination. J Thromb Haemost 2004; 2; 1946-53.
30. Tripodi A. How to implement the modified international normalized ratio for cirrhosis (INR liver) for model of end-stage liver disease calculation. Hepatology 2007; in press.
31. Quick AJ. The prothrombin in hemophilia and in obstructive jaundice. J Biol Chem 1935; 109: 73-4.